| Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ... New England Journal of Medicine 386 (7), 629-639, 2022 | 334 | 2022 |
| Targeting BTK in CLL: beyond ibrutinib DA Bond, JA Woyach Current hematologic malignancy reports 14, 197-205, 2019 | 118 | 2019 |
| Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, ... Blood, The Journal of the American Society of Hematology 137 (3), 374-386, 2021 | 89 | 2021 |
| Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era JN Gerson, E Handorf, D Villa, AS Gerrie, P Chapani, S Li, LJ Medeiros, ... Journal of Clinical Oncology 37 (6), 471-480, 2019 | 87 | 2019 |
| Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome AS Kittai, DA Bond, B William, A Saad, S Penza, Y Efebera, K Larkin, ... Blood Advances 4 (19), 4648-4652, 2020 | 68 | 2020 |
| Second cancer incidence in CLL patients receiving BTK inhibitors DA Bond, Y Huang, JL Fisher, AS Ruppert, DH Owen, EM Bertino, ... Leukemia 34 (12), 3197-3205, 2020 | 66 | 2020 |
| Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma RW Merryman, L Castagna, L Giordano, VT Ho, P Corradini, A Guidetti, ... Leukemia 35 (9), 2672-2683, 2021 | 59 | 2021 |
| The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib AS Kittai, C Miller, D Goldstein, Y Huang, LV Abruzzo, K Beckwith, ... Blood, The Journal of the American Society of Hematology 138 (23), 2372-2382, 2021 | 44 | 2021 |
| NX-2127-001, a first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B … AR Mato, WG Wierda, WZ Ai, IW Flinn, M Tees, MR Patel, K Patel, ... Blood 140 (Supplement 1), 2329-2332, 2022 | 39 | 2022 |
| CAR T-cell therapy for B-cell lymphoma N Denlinger, D Bond, S Jaglowski Current problems in cancer 46 (1), 100826, 2022 | 39 | 2022 |
| Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma RW Merryman, RA Redd, T Nishihori, J Chavez, Y Nieto, JM Darrah, ... Blood Advances 5 (6), 1648-1659, 2021 | 36 | 2021 |
| Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics P Torka, SK Kothari, S Sundaram, S Li, LJ Medeiros, EC Ayers, ... Blood advances 4 (2), 253-262, 2020 | 34 | 2020 |
| HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis JP Alderuccio, AJ Olszewski, AM Evens, GP Collins, AV Danilov, M Bower, ... Blood advances 5 (14), 2852-2862, 2021 | 33 | 2021 |
| Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure EC Ayers, S Li, LJ Medeiros, DA Bond, KJ Maddocks, P Torka, ... Cancer 126 (2), 293-303, 2020 | 32 | 2020 |
| Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study AS Zayac, AM Evens, A Danilov, SD Smith, D Jagadeesh, LA Leslie, ... Haematologica 106 (7), 1932, 2021 | 28 | 2021 |
| Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy DA Bond, JM Switchenko, D Villa, K Maddocks, M Churnetski, AS Gerrie, ... Blood advances 5 (23), 5179-5189, 2021 | 25 | 2021 |
| Bias and racism teaching rounds at an academic medical center Q Capers IV, DA Bond, US Nori Chest 158 (6), 2688-2694, 2020 | 23 | 2020 |
| Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: analysis of the phase III Belinda study MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ... Blood 138, LBA-6, 2021 | 21 | 2021 |
| Relapsed mantle cell lymphoma: current management, recent progress, and future directions DA Bond, P Martin, KJ Maddocks Journal of Clinical Medicine 10 (6), 1207, 2021 | 19 | 2021 |
| Current role and emerging evidence for bruton tyrosine kinase inhibitors in the treatment of mantle cell lymphoma DA Bond, KJ Maddocks Hematology/Oncology Clinics 34 (5), 903-921, 2020 | 19 | 2020 |
